Mustang Bio Files 8-K on Shareholder Vote Matters

TL;DR

Mustang Bio filed an 8-K on shareholder votes as of Dec 26, 2024. Details to follow.

AI Summary

Mustang Bio, Inc. filed an 8-K on January 2, 2025, reporting on matters submitted to a vote of security holders as of December 26, 2024. The filing details the company's principal executive offices located at 377 Plantation Street, Worcester, Massachusetts, and its telephone number. No specific voting outcomes or proposals were detailed in the provided text.

Why It Matters

This filing indicates that Mustang Bio held a vote of its security holders, which could pertain to significant corporate actions or governance changes that may impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote matter without immediate financial or operational impact detailed in the provided text.

Key Players & Entities

• Mustang Bio, Inc. (company) — Registrant
• December 26, 2024 (date) — Date of earliest event reported
• January 2, 2025 (date) — Filing date
• 377 Plantation Street, Worcester, Massachusetts (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share MBIO Nasdaq Capital Marke

Filing Documents

• tm251702d1_8k.htm (8-K) — 32KB
• 0001104659-25-000343.txt ( ) — 200KB
• mbio-20241226.xsd (EX-101.SCH) — 3KB
• mbio-20241226_lab.xml (EX-101.LAB) — 33KB
• mbio-20241226_pre.xml (EX-101.PRE) — 22KB
• tm251702d1_8k_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. Mustang Bio, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting") on December 26, 2024, by means of an online virtual meeting platform at 9:00 a.m. Eastern Time. At the Annual Meeting, the following two proposals were approved: (i) the election of seven directors to hold office until the 2025 annual meeting of stockholders; and (ii) the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The two proposals are described in detail in the Company's definitive Proxy Statement on Schedule 14A for the Annual Meeting, filed with the Securities and Exchange Commission on December 6, 2024. As of December 4, 2024, the record date for the determination of the shareholders entitled to notice of, and to vote at, the Annual Meeting, 48,768,863 shares of the Company's Common Stock were outstanding and eligible to vote with an aggregate of 48,768,863 votes; 845,385 shares of the Company's Class A Common Stock were outstanding and eligible to vote with an aggregate of 56,359 votes; and 250,000 shares of the Company's Class A Preferred Stock were outstanding and eligible to vote with an aggregate of 53,726,077 votes, as determined in accordance with the Company's Amended and Restated Certificate of Incorporation. Approximately 58% of all votes were represented at the Annual Meeting, constituting a quorum. Proposal 1 The votes with respect to the election of seven directors to hold office until the 2025 annual meeting of stockholders were as follows: Director For Withheld Broker Non-Votes Michael S. Weiss 58,341,063 1,127,036 0 Manuel Litchman, M.D. 58,774,775 693,324 0 Lindsay A. Rosenwald, M.D. 58,357,788 1,110,311 0 Neil Herskowitz 58,737,407 730,692 0 David Jin 58,830,033 638,066 0 Adam Chill 58,881,270 586,829 0 Michael Zelefsky, M.D. 58,894,954

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mustang Bio, Inc. Date: January 2, 2025 By: /s/ Manuel Litchman, M.D. Name: Manuel Litchman, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR